Related Experiment Video
Updated: May 16, 2026
06:06
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
S100A9 and tumor growth
Tomas Leanderson1, Fredrik Ivars
1Immunology Group; Lund University; Lund, Sweden.
Oncoimmunology
|December 18, 2012
Summary
The calcium-binding protein S100A9 is crucial for tumor growth in prostate cancer and T-cell lymphoma. Its interaction with Toll-like receptor 4 (TLR4) drives cancer progression in these models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- S100A9 is a calcium-binding protein implicated in various cellular processes.
- Aberrant expression of S100A9 has been observed in several cancer types.
- Toll-like receptor 4 (TLR4) is involved in innate immunity and inflammation, and its role in cancer is increasingly recognized.
Purpose of the Study:
- To investigate the role of S100A9 in tumor growth within prostate cancer and T-cell lymphoma models.
- To elucidate the specific molecular mechanisms by which S100A9 influences cancer progression.
- To determine the significance of the S100A9-TLR4 axis in these malignancies.
Main Methods:
- Utilized established prostate cancer and T-cell lymphoma cell lines and xenograft models.
- Assessed S100A9 expression levels through techniques such as immunohistochemistry and Western blotting.
- Investigated the functional interaction between S100A9 and TLR4 using co-immunoprecipitation and reporter assays.
Main Results:
- S100A9 expression was found to be elevated in both prostate cancer and T-cell lymphoma models.
- Inhibition of S100A9 expression significantly impaired tumor growth in vivo and in vitro.
- The interaction between S100A9 and TLR4 was demonstrated to be essential for mediating pro-tumorigenic effects.
Conclusions:
- S100A9 plays a critical role in promoting tumor growth in prostate cancer and T-cell lymphoma.
- The interaction of S100A9 with TLR4 is a key mechanism driving cancer progression in these settings.
- Targeting the S100A9-TLR4 pathway represents a potential therapeutic strategy for these hematological and solid tumors.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...